Navigation Links
GenVec Achieves Second Milestone in Collaboration
Date:12/6/2011

GAITHERSBURG, Md., Dec. 6, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) today announced that it has achieved the second milestone in its collaboration with Novartis (NYSE: NVS), related to the development of treatments for hearing loss and balance disorders. The milestone was triggered by the successful completion of certain preclinical development activities.

"Completing this milestone reflects sustained progress and we look forward to reaching additional milestones with Novartis in this very exciting program," said Dr. Paul Fischer, GenVec's President and Chief Executive Officer.

About the CollaborationIn January 2010, GenVec entered into a worldwide licensing and collaboration agreement with Novartis to discover and develop novel treatments for hearing loss and balance disorders. Under the terms of the agreement, if certain clinical, regulatory, and sales milestones are met, GenVec is eligible to receive up to $213.6 million, including upfront and milestone payments in addition to royalties on future sales.

In August 2010, we entered into an additional agreement with Novartis, to manufacture clinical trial material for up to two lead product candidates for this program.

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss a
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. GenVec Reports Third Quarter 2009 Financial Results
8. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
10. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
11. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , ... August 03, 2015 , ... Nine field days ... Illinois and Indiana. Hosted by the Soil Health Partnership , the field days ... environmental benefits while potentially increasing farm productivity and income. , Brent Bible has practiced ...
(Date:8/3/2015)... 2015 E-QURE Corp. (OTCQB: EQUR), ... Bio-electrical Signal Therapy device ("BST Device"), a new and ... heal chronic wounds, today announced that the Company has ... distributor specializing in medical devices, for the marketing and ... a 70 years old, sales, marketing and distribution company ...
(Date:8/3/2015)... -- According to a new market report ... Asia to Witness Highest Growth by ... culture market was valued at US$ 586.1 Mn in 2014 ... 29.1% to account for US$ 2,717.6 Mn by 2020. ... 3D cell culture refers to a process ...
(Date:8/3/2015)... ... 2015 , ... Sterlitech Corporation introduces the compact, quiet, and ... laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, an oil-free design, ... solution for a broad range of vacuum filtration applications. , Featuring a 1/7 ...
Breaking Biology Technology:Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4Sterlitech Launches New Line of Vacuum Pumps 2
... June 30, 2011 Dendreon Corporation (Nasdaq: ... support broad availability for on-label use of PROVENGE® ... treatment of asymptomatic or minimally symptomatic metastatic castrate ... The U.S. Food and Drug ...
... 2011 ( HCCS ) Health Care Compliance Strategies, ... competency training, today announced the release of an update ... SimPL - The Simple Platform for Learning. This ... existing online training and eLearning functions. (Logo: ...
... National Parkinson Foundation (NPF) has awarded more than $1 ... individual investigators awards program, NPF is supporting work to advance ... biomarker study, 2) a clinical trial to treat memory impairment, ... for sleep apnea in PD. "Each of these ...
Cached Biology Technology:Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 2Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 3Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 4HCCS Releases Classroom Management Features for Low Cost Learning Management System 2National Parkinson Foundation Awards More Than $1 Million for Research 2National Parkinson Foundation Awards More Than $1 Million for Research 3
(Date:8/3/2015)... JOSE, Calif. , Aug. 3, 2015 ... of human interface solutions, today announced that members of ... community at the Pacific Crest Global Technology Leadership Forum ... Time. The conference will be held at the Sonnenalp ... The presentation may include forward-looking information. An ...
(Date:7/31/2015)... de julio de 2015 La 10 th ... por medio de BGI del 22 al 25 de octubre de ... Este año, la conferencia celebra su décimo aniversario. Desde ... en una de las reuniones anuales más influyentes del mundo ... reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. ... human interface solutions, today announced that Huawei has ... touchscreen solution for its stylish smartwatch. Huawei chose ... proven reliability, low power and highly responsive human ... finger. Huawei designers also required a classic round ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... in Oregon,s Willamette Basin to protect at-risk animals won,t ... will absorb more carbon from the atmosphere and vice ... study, to be published this month in the ... hypothetical payments that were given to landowners to voluntarily ...
... UC San Diego are collaborating with scientists from ... map patterns of biodiversity and land use in ... with climate models, will project how climate change ... for setting aside conservation easements. Wildlife, people ...
... Francisco Gonzlez, president of the BBVA Foundation: "One of the ... the environment and, especially, of biodiversity. This is a task ... all play our part. At BBVA, we believe it is ... of the natural resource base" United States researchers ...
Cached Biology News:Incentives for carbon sequestration may not protect species 2Biodiversity maps developed by UCSD scientists will help guide conservation measures in East Africa 2Biodiversity maps developed by UCSD scientists will help guide conservation measures in East Africa 3BBVA Foundation Awards for Biodiversity Conservation 2BBVA Foundation Awards for Biodiversity Conservation 3BBVA Foundation Awards for Biodiversity Conservation 4
Mycoplasma and virus tested...
Bethyl Laboratories Ready-To-Use IHC Bluing Reagent is used following IHC hematoxylin counterstaining with immunohistochemical procedures. Shelf-Life: 1 year from date of receipt...
Edited by Benjamin Lewin (1997) • This book gives an integrated account of the structure and function of genes in both prokaryotic organisms and is thoroughly up to date with the latest thinking...
... is the most effective ... PCR products. TOPO TA ... TOPO vectors are supplied ... topoisomerase I. This enables ...
Biology Products: